Abstract Search

ea0056p882 | Pituitary - Clinical | ECE2018

Efficacy and tolerability of cabergoline in a cohort of 160 prolactinomas at weekly doses of up to 9 mg

Vilar Lucio , Vilar Clarice , Albuquerque Luciano , The Ana Carolina , Trovao Erik , Gadelha Patricia , Sampaio Icaro , Gomes Barbara , Ferreira Liana , Aroucha Priscila , Lyra Raissa , Fonseca Maira , Lyra Ruy

Background: Dopamine agonists are the mainstay of treatment for prolactinomas. Cabergoline (CAB) is preferable to bromocriptine due to its greater efficacy and better tolerability.Subjects and methods: The aim of this retrospective open trial was to evaluate the efficacy and tolerability of CAB in a cohort of 160 patients with prolactinomas routinely followed in Pernambuco Endocrine Research Center and Division of Endocrinology, Hospital das Clinicas, Fe...

0 shares

ea0056p888 | Pituitary - Clinical | ECE2018

Lanreotide autogel may be an effective approach for acromegalic patients who failed octreotide lar

Vilar Lucio , Vilar Clarice , Albuquerque Luciano , Trovao Erik , The Ana Carolina , Sampaio Icaro , Ferreira Liana , Cardoso Izabela , Borges Thaise , Aroucha Priscila , Gadelha Patricia , Lyra Ruy

Background: Growth hormone secreting pituitary gland adenomas specifically express somatostatin (SST)-2 and SST5 receptors. First-generation somatostatin analogs (octreotide and lanreotide) are the mainstay in the medical treatment of acromegaly, however the percentage of patients controlled with these drugs significantly varies in the different studies (2070%). Many factors are involved in the resistance to SRL somatostatin analogs such as sst, AIP, E-cadherin, ZAC1, fi...

0 shares

Endocrine Abstracts

Efficacy and tolerability of cabergoline in a cohort of 160 prolactinomas at weekly doses of up to 9 mg

Lanreotide autogel may be an effective approach for acromegalic patients who failed octreotide lar

BiosciAbstracts